Responses
Clinical and epidemiological research
Extended report
Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial
Compose a Response to This Article
Other responses
No responses have been published for this article.